New antibody cocktail takes on tough lupus kidney disease
NCT ID NCT06975787
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can help reduce steroid use and improve kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bispecific antibodies (vonsetamig and odronextamab)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat lupus nephritis, potentially reducing the need for steroids.
- What could go wrong
- This is an early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. The drugs may cause side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
-
Centre Hospitalier Universitaire (CHU) Bordeaux
RECRUITINGBordeaux, New Aquitaine, 33076, France
-
Changhua Christian Hospital
RECRUITINGChanghua, 500, Taiwan
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
-
Hallym University Sacred Heart Hospital
RECRUITINGAnyang-si, Gyeonggi-do, 14068, South Korea
-
Hospital Gregorio Maranon
RECRUITINGMadrid, 28007, Spain
-
Hospital Regional Universitario de Malaga
RECRUITINGMálaga, 290090, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, Andalusia, 41013, Spain
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
National Taiwan University Hospital
RECRUITINGTaipei, 106, Taiwan
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Taichung General Veterans Hospital
RECRUITINGTaichung, 40705, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
-
University Hospital Regensburg
RECRUITINGRegensburg, Bavaria, D-93053, Germany
-
University Medical Center of the Johannes Gutenberg-University Mainz
RECRUITINGMainz, 55131, Germany
-
Yonsei University College of Medicine, Severance Hospital
RECRUITINGSeoul, 3722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Blood traps may reveal lupus kidney treatment success
- A simple blood marker may reveal hidden heart risks in lupus
- Can a gentler steroid dose protect children's kidneys without the harsh side effects?
- Could a diabetes drug shield kidneys in lupus?
- Experimental drug aims to protect kidneys in inflammatory diseases